Towards a European Consensus on Conducting and Reporting Health Economic Evaluations—A Report from the ISPOR Inaugural European Conference  by Goetghebeur, Mireille M. & Rindress, Donna
 Volume 2 • Number 4 • 1999
VALUE IN HEALTH
 
© ISPOR 1098-3015/99/$14.00/281 281–287
 
281
 
Towards a European Consensus on Conducting and Reporting 
Health Economic Evaluations—A Report from the ISPOR 
Inaugural European Conference
 
Mireille M. Goetghebeur, PhD, Donna Rindress, PhD
A B S T R A C T
 
BioMedCom Consultants inc, Montréal, Québec, Canada
 
This report is a summary of key issues in consensus de-
velopment regarding the conduct and reporting of health
economic research in the European context, presented
and discussed at the ISPOR Inaugural European Confer-
ence in Cologne, Germany, December 1998. Recommen-
dations of the Harmonization by Consensus of the Meth-
odology for Economic Evaluation of Health Care
Technologies in the European Union (HARMET) project
were presented, as well as two instruments under devel-
opment: software for Reporting Economic Evaluation
Results (REER) and software for collecting and manag-
ing cost data called the Health Cost Database Software
(HCDS). Working independently, but interrelated with
the objectives of the HARMET initiative, preliminary re-
sults from the ongoing European Network on Methodol-
ogy and Application of Economic Evaluation Techniques
(EUROMET) project were presented. Each presentation
was followed by an expert discussion panel with audi-
ence participation. Issues raised included the develop-
ment of standards and related topics such as usefulness
to European decision-makers, and education and train-
ing in health economics in Europe.
 
B
 
ecause of its diversity, Europe faces a unique
challenge in conducting and reporting health
economic evaluation in a fashion that is meaningful
to the whole European Community (EC). Stan-
dardization was seen as necessary to allow broader
use of study results across European borders. Two
European Commission projects were initiated to
seek solutions to key issues in the development of
health economic research in Europe.
The project on Harmonization by Consensus of
the Methodology for Economic Evaluation of
Health Care Technologies in the European Union
(HARMET) was initiated in 1994 and completed in
1997. Ten countries were represented by 23 partici-
pants. HARMET objectives were to propose recom-
mendations that would standardize health economic
evaluation and to improve transparency, compara-
bility, and relevance to decision-makers. Begun in
1996 after the HARMET initiative with comple-
mentary objectives, the European Network on
Methodology and Application of Economic Evalua-
tion Techniques project (EUROMET) should be
completed in 1999. Fourteen researchers from 11
countries participated; its aims were to identify cur-
rent practices related to the conduct and application
of health economic evaluation in Europe and to pro-
pose recommendations to augment its usefulness to
European healthcare decision-makers.
Highlights of these projects were presented at
the ISPOR European inaugural conference in Co-
logne, Germany, in December 1998 by Joan
Rovira, University of Barcelona, Spain (Chair of the
HARMET project) and J. Matthias Graf von der
Schulenburg from the University of Hanover, Ger-
many (Chair of the EUROMET project). The issues
were then discussed by an invited panel of experts
from several European countries with audience par-
ticipation. This report spotlights those issues of
consensus development in the conduct of health
economic evaluation within the European context.
 
Towards a European Standard Methodology 
for Health Economic Evaluation
 
Several valid reasons exist to standardize method-
ology in health economic evaluation across Eu-
rope. European standards would facilitate study
conduct and reduce costs. Greater standardization
would also enhance the understanding and accep-
tance of health economic evaluation at the level of
the decision-maker. In addition, with harmoniza-
tion of the European health services market, the
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EC seems to be evolving towards a single Euro-
pean healthcare system in which only standard
economic evaluation methodology will fit.
Methodological standards in health economic
evaluation were also considered to be the next step
towards improving the quality, transparency, and
comparability of studies. The literature reveals that
the quality of published studies can be improved [1].
Transparency was seen as essential in convincing
decision-makers that health economic evaluations
are not “black boxes” but rather credible scientific
research that can be validated by standards and con-
firmed by peers. Comparability is becoming par-
ticularly important in Europe to allow for the trans-
ferability of information between countries.
Because methodology is dependent on perspec-
tive, and health economic information must relate
to the perspective of decision-makers (which var-
ies not only between but within European coun-
tries), involvement of decision-makers in the har-
monization process is believed by participants to
be critical. As well, as changes in regulatory per-
spectives evolve, standards developed must be
flexible enough to allow ongoing adjustment.
Discussion panel participants agreed that stan-
dards should be developed in areas in which con-
sensus exists, while controversial areas should re-
main more flexible. The process of developing
consensus was considered to be on-going, which
should not terminate in “guidelines” but in stan-
dards based on defining principles. The ultimate
objective of these standards would be to ensure a
high level of quality and transparency. Also raised
was the concept of developing accounting conven-
tions at the European level defining which re-
source and associated cost should be included for
a given procedure.
 
Recommendations of the HARMET Group on 
Standardization of Methodology
 
Inspired by Canadian [2] and Australian guide-
lines [3], and based on the work of the US Panel on
Cost-effectiveness in Health and Medicine [4–6],
operational recommendations were elaborated un-
der the auspices of HARMET. Methodological
standards were developed from a European perspec-
tive, taking into consideration that there is not yet
a centralized decision-making body. The proposed
recommendations of HARMET focused on pro-
fessional and government bodies involved in stan-
dards setting for use as general guidelines, rather
than on researchers, and were prepared with the
principal objective of developing health economic
evaluation decision-making tools.
The HARMET recommendations were pre-
sented as a series of valid options from which us-
ers selected the most relevant alternatives to meet
their objectives (Table 1). Each recommended op-
tion was justified on the basis of theoretical uni-
versality, ethics, logical consistency, conventional-
ity, pragmatism or user convenience. Theoretical
recommendations stemmed from universally ac-
cepted principles or statements supported by em-
pirical evidence. Ethical recommendations were
based on value judgments. Logical consistency ap-
plied to options grounded in logic, mathematics or
accounting rules. Conventional alternatives were
based on tradition or consensus, while pragmatic
choices were forced by practical constraints. Rec-
ommendations based on a user convenience prin-
ciple aimed at facilitating the use of health eco-
nomic evaluation.
Recommendations were restricted to cost effec-
tiveness and cost utility analyses on the grounds
that these types of analyses are the most com-
 
Table 1
 
HARMET project recommendations for conducting health
economic evaluations
 
1. Define study perspective and justify selection of methodology
2. Define objective(s) in terms of the decision it is intended to inform
3. Select relevant and appropriate comparator(s), including the most efficient existing option
4. Select a time horizon that captures all relevant future effects
5. Apply discount rate that reflects only time preference (preferably)
6. Use same discount rate in a given comparison and for the whole time horizon
7. Modeling is a legitimate approach, as long as model is validated
8. Express outcome(s) in terms of a generic health status measure
9. Apply opportunity cost to evaluate resource use (preferably)
10. Societal cost is the relevant cost concept for societal perspective
11. Measure costs in constant monetary units of the reference year
12. Use absolute values, not just relative values (integral costing)
13. Select appropriate health outcome measure; use clinical event incidence whenever available
14. Use the general population for health status valuation when using the societal perspective
15. So far, QALYs seem preferable to HYEs
16. Use time trade-off or standard gamble approach for QALYs
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monly used in healthcare decision-making. Be-
cause the reference case proposal of the US panel
was considered too general to be useful in the Eu-
ropean context, no reference case was included in
the HARMET recommendations. It is believed
that the use of proposed methodological standards
will enhance the comparability and transparency
of studies and facilitate their quality assessment and
their replication. At termination of the HARMET
project, members felt it was necessary to seek
feedback from decision-makers and adjust the rec-
ommendations to their needs, moving health eco-
nomics into the real world. This was one of the
objectives of the EUROMET project.
 
Development of a Framework for European 
Guidelines: The EUROMET Project
 
In continuity with the HARMET project, EURO-
MET is currently exploring the development of a
framework for European guidelines for conduct-
ing health economic evaluation. A consensus pa-
per on methodological issues will be published
shortly, in which several issues (Table 2) will be
explored more fully. The key objective of the
EUROMET consensus paper is to propose a frame-
work for health economic guidelines. This frame-
work is not meant to replace national guidelines
already in place but to provide some methodologi-
cal standards that increase the usefulness of Euro-
pean health economic evaluation by ensuring high
quality and transparency, and by enhancing com-
parability. The EUROMET project also intends to
identify tools that can be used throughout Europe
to evaluate nonmonetary outcomes in health eco-
nomic evaluation.
 
Standardized Reporting is Desirable in the 
European Context
 
Both presenters and panelists agreed that standard-
ized reporting of health economic evaluation is desir-
able for transparency, comparability, and user con-
venience. Although transparency is essential for
credibility, however, it is not sufficient to make
health economic evaluation useful to or usable by
decision-makers. Information must be easy to under-
stand and to verify. Disaggregation is a key issue in
reporting health economic evaluation in a transpar-
ent fashion. It allows replication or adjustment of an
analysis to other settings, increasing its value and en-
hancing its versatility. This issue is particularly cru-
cial in Europe because of its great diversity.
 
The Recommendations of HARMET Concerning 
Reporting Health Economic Evaluation
 
Presentation of results was explored by the
HARMET project, which stressed the need for a
transparent reporting in a standardized format.
The following recommendations were made:
• At the very least, clinical outcomes, resource
utilization and unit cost (or value) of resources
should be disaggregated;
• Detailed reports should be made available on
request when reporting space is limited;
• All factors that might affect results should be
reported;
• Unavailability of relevant data should be re-
ported;
• A standardized terminology should be used;
• Presentation of both data and data analysis in
an electronic format should be encouraged.
To meet the need for electronic tools identified
by HARMET, two instruments were developed to
ease standard reporting of health economic evalu-
ation and to make studies transparent. These tools
allow the use of various sets of data and costs, and
include [7]:
• software for Reporting Economic Evaluation
Results (REER);
• software for collecting and managing cost data
called the Health Cost Database Software
(HCDS).
The REER software was developed to provide a
standard reporting structure using a disaggregated
format. If the program is fed with appropriate
data, REER software allows several types of anal-
yses. It is divided into three main sections. The
first section allows definition of options such as
 
Table 2
 
Methodological issues explored by EUROMET
 
Perspective: Different decision-making processes exist in European countries resulting in a variety of perspectives
Measurements of costs: This is a crucial issue in the European context, especially with respect to transferability between 
member countries
Quality of life instruments: The development of a gold standard for European countries is under way, keeping in mind that a variety 
of measurements will be needed to answer different questions
New statistical instruments: Specific tools will need to be adapted for health economic evaluation with two types of vector, one for
costs and utilization and one for quality of life and length of life
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treatment, comparators, and subjects. Analysis
can be performed for a specific target population
with defined life expectancies and risk factors, or
for a whole population. The data input section in-
cludes resource utilization, unit costs, health out-
comes, and discounting which can be linked with
other databases such as the HCDS. Cost and re-
source information are maintained as input data
files that allow modification at any time and that
permit easier translation of data from one setting
to another. Measures of effectiveness or outcome
can be modified. After feeding the program with
option and data information, the output is deter-
mined in terms of differences in cost and effect;
dominance analysis, incremental analysis, or sensi-
tivity analysis can be completed. This instrument
also allows sensitivity analyses to be tailored to
the needs of each end-user. This REER software is
presently at the prototype stage and is being tested
by potential users to obtain essential feedback.
The Health Cost Database Software (HCDS) is
a second instrument developed to meet the needs
identified by the HARMET project. It enables col-
lection, categorization, and storage of unit cost
data. European charges, although often assump-
tions, provide good proxy measures and are in-
cluded in the HCDS. Cost units are broken down
into procedure costs, hospital costs, and nonhos-
pital costs. Cost data can be traced back to its
source, allowing evaluation of the quality of the
data. The HCDS also contains a feature that ad-
justs for inflation. Similar to the cost listings avail-
able in Australia and Canada, the preparation of a
list of unit costs for European countries was con-
sidered a potentially useful resource in the harmo-
nization of health economic evaluation.
As in any other scientific domain, methodology
should be sufficiently transparent to allow the
reader to reproduce results. It was recommended
that models be published separately and put into
the public domain. Only transparent studies
should be considered acceptable evidence; no
compromise of scientific transparency in the field
of health economics should be allowed. Although
the HARMET group made no recommendation
concerning development of a code of ethics, it was
emphasized that the standard ethical practices of
biomedical research scientists should be applied.
 
The Usefulness of Health Economic 
Evaluation to European Decision-makers
 
One key issue in the future of health economics is
identification and satisfaction of the needs of
healthcare decision-makers [8]. The development
of a closer relationship between researchers and
decision-makers is particularly crucial in Europe
where a communication barrier exists between the
healthcare system and industry. On top of this,
European healthcare systems themselves are gen-
erally not transparent and are often compartmen-
talized. Such structure creates barriers to global
decision-making and the application of health eco-
nomic evaluation. For example, in the UK, the in-
flexibility of the British National Health Service
was reported as a major barrier to the use of
health economic evaluation [9].
As a rule, decision-makers need reliable results
that are relevant to their setting and their perspec-
tive. They are interested in both the effectiveness
of a therapy and its associated resource and cost
consequences, but not necessarily in cost-effective-
ness ratios or other types of technical analyses.
Technicality of language and lack of standardiza-
tion have a strong negative impact on the percep-
tion of health economic evaluation. Poor presenta-
tion of evaluation objectives and the perceived
strategies of the pharmaceutical industry contrib-
ute to the common impression of decision-makers
that health economic evaluation serves only to
support high prices. It was proposed that health
economic evaluation should be used more in pro-
filing therapies (that is, helping to define target
populations and therapeutic strategies) and not
only in pricing justification. Development of stan-
dards for the conduct and reporting of health eco-
nomic evaluations would increase its acceptability
and help move health economics away from the
“black box” syndrome.
 
New Tools are Needed to Meet the Needs
of Decision-makers
 
Among the many factors involved, reliable evi-
dence and strong arguments were considered cru-
cial in order for health economic evaluation to
play a stronger role in healthcare decision-making.
Decision-makers expressed interest in estimates of
affordability as well as suggestions about financ-
ing novel cost-effective procedures that require ad-
ditional resources. New ideas related to decom-
partmentalizing in healthcare budgets were also
needed, that is, approaches to operating under a
system based on annual budgets when health eco-
nomic evaluation extends over several years. An-
other area of need was postmarketing surveil-
lance, in terms of resource utilization and costs.
New health economic research methodology was
seen as necessary to enhance the ability of health
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economists to provide the information that is re-
ally needed.
 
The EUROMET Survey of European Decision-makers
 
One objective of the EUROMET group was as-
sessment of the influence of health economic eval-
uation on healthcare decision-making in European
countries. A survey of decision-makers from each
European country was performed. Three different
approaches were used: mailed questionnaires, in-
dividual interviews, and round-table discussions.
Preliminary results of this survey (Fig. 1) indicated
a positive attitude towards health economic evalu-
ation, which was considered increasingly important
in healthcare resource allocation. Decision-makers’
understanding of health economic evaluation tech-
niques was moderate and sophisticated studies
were not well understood; health economic evalu-
ations were often considered “black boxes.” This
led to limited use of health economic evaluation as
a decision-making tool and a need for more guid-
ance on its interpretation and use. Survey results
indicated several barriers to be overcome.
 
Education and Training in Health Economics 
in the European Context
 
Future growth and development of health eco-
nomic research and its application to healthcare
decision-making depends on the availability of ed-
ucational resources to train skilled professionals in
the field. The recommendations of the US Advi-
sory Panel on Issues in Pharmacoeconomics [10]
were considered to apply equally in Europe. Basic
requirements for training researchers in the field
included a mix of medicine and economics; it was
felt that more collaboration between these fields
should be developed. It was also proposed that
those with business backgrounds (such as MBA
students) be encouraged to train in the healthcare
sector. Along these lines, the University of Hanover
and the Medical School of Hanover in Hanover,
Germany proposed a postgraduate study program
in health economics and health management.
For those already at work in the health eco-
nomic domain, there is still a considerable need
for further training in health economics. It was
generally agreed that developing programs should
Figure 1 Preliminary results of the EUROMET survey.
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include trainers representing all health economic
perspectives, including academia, industry, and
healthcare and health policy regulators. To date,
only a few programs train clinicians and clinical
administrators or health economists working in
the pharmaceutical industry (see Table 3).
Availability of information about training and
education was a concern for many. Following on
an earlier recommendation of the US Advisory
Panel on Issues in Pharmacoeconomics: Education
[10], a worldwide directory of educational pro-
grams and fellowships in health economics is un-
der development and can be viewed on the ISPOR
website (www.ispor.org). This should be an in-
creasingly important source of this type of infor-
mation.
 
Future Trends and Recommendations
 
The recommendations proposed by the HARMET
group, and the instruments developed subse-
quently to foster standardization of health eco-
nomic evaluation in Europe, are not yet publicly
available. The still ongoing EUROMET project
should provide useful insight into applicability
and implementability of standards in the Euro-
pean context. Among recommendations arising
from the discussion panels were:
• European standards that included auditing and
registering procedures might also be used to in-
crease the acceptability and credibility of health
economic evaluation. Originally proposed by
Uwe Rheinardt [11], third party auditors could
examine economic evaluations and evaluate
compliance according to defined standards.
• A strong recommendation was made for a Eu-
ropean register of health economic evalua-
tions. Such a register would promote more
standard methodology and increase the avail-
ability of information and awareness of on-
going studies and expected results.
Panelists concurred that a significant part of fu-
ture development in this field lies in integration of
standardized health economic data into evidence-
based guidelines, which they believed to be an
important potential decision-making tool in the
future [12]. Incorporation of resource and cost
consequence data into these guidelines would en-
hance the value of health economic research to
healthcare decision-making. The first step will be
to provide a framework that permits identification
of relevant resources and costs and evaluation of
the potential impact of these proposed guidelines
on hospital resources, primary care resources, so-
cial services, families, and patients. European
standards for health economic evaluation that in-
corporate this information should dramatically
enhance the usefulness and credibility of health
economic research to healthcare decision-makers.
 
This report is based on the presentations of Joan Rovira,
PhD, SOIKOS, Department of Economics, University of
Barcelona, Spain, and J. Matthias Graf von der Schulen-
burg, PhD, Centre for Health Economics and Health Sys-
tem – HSR, University of Hanover, Germany, and on en-
suing panel discussions in which contributions were made
by Jonathan Cooke Mpharm, PhD, South Manchester
University Hospitals, Manchester, UK; Michael Drum-
mond, PhD, University of York, Centre for Health Eco-
nomics, York, UK; Livio Garattini, MD, CESAV Centre
for Health Economics, Institute for Pharmacological Re-
search, Ranica, Italy; Bengt G. Jönsson, PhD, Stockholm
School of Economics, Stockholm, Sweden; Karl W. Lauter-
bach, MD, ScD, Institute for Health Economics, Univer-
sity of Cologne, Germany; and Frank Peys, Belgian Insti-
tute for Health Economics, Brussels, Belgium.
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